



**B Hirschel**

**Kontakt**

B Hirschel

## Publikationen (26)

Ananworanich J, Hirschel B, Ruxrungtham K, Cooper D, Jupimai T, Ubolyam S, Mahanontharit A, Chotnopparatpattara P, Chaithongwongwatthana S, Mangclaviraj S, Vernazza P, Kerr S, and the Staccato HIV-NAT Study Group. Genital shedding of HIV after scheduled treatment interruption. *Int J STD AIDS* 2011; 22:61–6.

El Amari E, Hirschel B, Bernasconi E, Hirsch H, Vernazza P, Cavassini M, Furrer H, Hasse B, Kaiser L, Calmy A, Yerly S, Combescure C, Swiss HIV Cohort Study. Clinical relevance of cytomegalovirus viraemia(\*, †). *HIV Med* 2011; 12:394–402.

Magenta L, Bernasconi E, Bucher H, Decosterd L, Cavassini M, Evison J, Vernazza P, Hirschel B, Flepp M, Hasse B, Young J, Richter W, Dell-Kuster S, the Swiss HIV Cohort Study (SHCS). Lipid and Lipoprotein Profile in HIV-Infected Patients Treated with Lopinavir/Ritonavir as a Component of the First Combination Antiretroviral Therapy. *AIDS Res Hum Retroviruses* 2010

Young J, Bucher H, Battegay M, Hirschel B, Vernazza P, Bernasconi E, Cavassini M, Fux C, Rickenbach M, Böni J, Yerly S, Opravil M, Günthard H, Scherrer A, for the Swiss HIV Cohort Study. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. *HIV Med* 2010

Ledergerber B, Weber R, Rickenbach M, Furrer H, Hirschel B, Vernazza P, Bernasconi E, Battegay M, Cavassini M, and the Swiss HIV Cohort Study (SHCS). Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study(\*). *HIV Med* 2010

Combescure C, Hirschel B, Vernazza P, Bernasconi E, Battegay M, Rauch A, Furrer H, Cavassini M, Ledergerber B, Vallier N, Swiss HIV Cohort Study. How reliable is an undetectable viral load?. *HIV medicine* 2009; 10:470–6.

Weber R, Ledergerber B, Schmid P, Bernasconi E, Cavassini M, Hirschel B, Elzi L, Furrer H, Rickenbach M, Huber M, Swiss HIV Cohort Study. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. *HIV medicine* 2009; 10:407–16.

Wunder D, Furrer H, Mueller B, Bernasconi E, Schmid P, Elzi L, Cavassini M, Hirschel B, Mueller N, Bersinger N, Fux C, Swiss HIV Cohort Study. Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipodystrophy during antiretroviral therapy: a case-control study. *HIV medicine* 2008; 9:427–32.

Wolbers M, Battegay M, Hirschel B, Bernasconi E, Schmid P, Weber R, Cavassini M, Rickenbach M, Furrer H, Bucher H, Swiss HIV Cohort Study. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. *HIV medicine* 2008; 9:397–405.

Nguyen A, Hirschel B, Perneger T, Schmid P, Tarr P, Evison J, Opravil M, Battegay M, Bernasconi E, Schiffer V, Calmy A, Swiss HIV Cohort Study. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006. *HIV medicine* 2008; 9:142–50.

Glass T, Bucher H, Battegay M, Hirschel B, Cavassini M, Bernasconi E, Furrer H, Rickenbach M, Vernazza P, Weber R, Wolbers M, Ungsedhapand C, Swiss HIV Cohort Study. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. *HIV medicine* 2006; 7:404–10.

Bucher H, Battegay M, Minder C, Vernazza P, Bernasconi E, Weber R, Hirschel B, Telenti A, Furrer H, Taffé P, Bichsel M, Swiss HIV Cohort Study. Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naïve HIV-infected patients: the Swiss HIV Cohort Study. *HIV medicine* 2002; 3:247-53.

Yerly S, Perrin L, Hirschel B, Rickenbach M, Bru J, Veuthey A, Battegay M, Telenti A, Flepp M, Vernazza P, Chave J, Rizzardì P, Vora S, Swiss HIV Cohort Study. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. *AIDS (London, England)* 2001; 15:2287-92.

Boubaker K, Francioli P, Rickenbach M, Opravil M, Egger M, Bernasconi E, Chave J, Boggian K, Hirschel B, Haensel A, Furrer H, Sudre P, Flepp M, Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. *Clin Infect Dis* 2001; 33:1931-7.

Fellay J, Telenti A, Flepp M, Greub G, Francioli P, Vernazza P, Hirschel B, Battegay M, Furrer H, Bernasconi E, Ledergerber B, Boubaker K, Swiss HIV Cohort Study. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. *Lancet* 2001; 358:1322-7.

Bernasconi E, Vernazza P, Bernasconi A, Hirschel B, Swiss HIV Cohort Study. HIV transmission after suspension of highly active antiretroviral therapy. *Journal of acquired immune deficiency syndromes (1999)* 2001; 27:209.

Battegay M, Hirschel B, Bedoucha V, Morgenthaler S, Jaccard C, Malinverni R, Erb P, Sendi P, Flepp M, Bernasconi E, Vernazza P, Swiss HIV Cohort Study. Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naïve patients. *HIV medicine* 2001; 2:35-42.

Greub G, Flepp M, Francioli P, Janin P, Hirschel B, Piffaretti J, Boggian K, Erb P, Bürgisser P, Furrer H, Perrin L, Grob P, Battegay M, Ledergerber B, Telenti A. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. *Lancet* 2000; 356:1800-5.

Rutschmann O, Perrin L, Leduc D, Fagard C, Bernasconi E, Malinverni R, Telenti A, Ledergerber B, Opravil M, Bucher H, Vernazza P, Hirschel B. Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. *Swiss HIV Cohort Study. AIDS (London, England)* 2000; 14:2145-51.

Vernazza P, Bernasconi E, Hirschel B. [HIV superinfection: myth or reality?]. *Schweizerische medizinische Wochenschrift* 2000; 130:1101-4.

Ledergerber B, Francioli P, Sudre P, Kaufmann D, Opravil M, Bernasconi E, Vernazza P, Battegay M, Furrer H, Hirschel B, Weber R, Erard V, Egger M, Telenti A. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. *JAMA : the journal of the American Medical Association* 1999; 282:2220-6.

Zinkernagel C, Ledergerber B, Battegay M, Cone R, Vernazza P, Hirschel B, Opravil M. Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. *Swiss HIV Cohort Study. AIDS (London, England)* 1999; 13:1587-9.

Furrer H, Flepp M, Rickenbach M, Vernazza P, Telenti A, Battegay M, Hirschel B, Bernasconi E, Opravil M, Egger M, Malinverni R. Discontinuation of primary prophylaxis against *Pneumocystis carinii* pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. *Swiss HIV Cohort Study. The New England journal of medicine* 1999; 340:1301-6.

Ledergerber B, Francioli P, Furrer H, Flepp M, Sudre P, Vernazza P, Battegay M, Hirschel B, Telenti A, Opravil M, Egger M, Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. *Swiss HIV Cohort Study. Lancet* 1999; 353:863-8.

Rutschmann O, Perrin L, Yerly S, Leduc D, Sudre P, Bernasconi E, Bucher H, Vernazza P, Malinverni R, Iten A, Opravil M, Hirschel B. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. *The Swiss HIV Cohort Study. AIDS (London, England)* 1998; 12:F71-7.

Rutschmann O, Yerly S, Perrin L, Bernasconi E, Bucher H, Vernazza P, Malinverni R, Iten A, Opravil M, Hirschel B. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. *Swiss HIV Cohort Study. Antiviral therapy* 1998; 3 Suppl 4:65-7.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)